Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma

Saved in:

Bibliographic Details
Main Authors:	Maura C. Gillis, BA, Vanessa R. Weir, BA, Cecilia Lezcano, MD, Gopa Iyer, MD, Allison Gordon, MD
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	JAAD Case Reports
Subjects:	bullous dupilumab enfortumab vedotin flexural oncodermatology pembrolizumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S235251262400417X
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet